
Daniel R. Carcanague
Examiner (ID: 2308)
| Most Active Art Unit | 1625 |
| Art Unit(s) | 1625, 1621 |
| Total Applications | 1094 |
| Issued Applications | 878 |
| Pending Applications | 31 |
| Abandoned Applications | 208 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19541647
[patent_doc_number] => 20240358683
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-31
[patent_title] => COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASE COMPRISING COMPOUND INDUCING EXPRESSION OF ANTI-AGING GENE KLOTHO
[patent_app_type] => utility
[patent_app_number] => 18/553414
[patent_app_country] => US
[patent_app_date] => 2022-03-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11502
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18553414
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/553414 | COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASE COMPRISING COMPOUND INDUCING EXPRESSION OF ANTI-AGING GENE KLOTHO | Mar 27, 2022 | Pending |
Array
(
[id] => 17718950
[patent_doc_number] => 20220211669
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-07
[patent_title] => Methods, Agents, and Compositions for the Treatment of Acute Myeloid Leukemia
[patent_app_type] => utility
[patent_app_number] => 17/699793
[patent_app_country] => US
[patent_app_date] => 2022-03-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13392
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17699793
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/699793 | Methods, agents, and compositions for the treatment of acute myeloid leukemia | Mar 20, 2022 | Issued |
Array
(
[id] => 17896956
[patent_doc_number] => 20220306618
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-29
[patent_title] => DERIVATIVES OF SUBSTITUTED MORPHOLINES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/698592
[patent_app_country] => US
[patent_app_date] => 2022-03-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8720
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17698592
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/698592 | Derivatives of substituted morpholines and uses thereof | Mar 17, 2022 | Issued |
Array
(
[id] => 18511297
[patent_doc_number] => 20230227433
[patent_country] => US
[patent_kind] => A9
[patent_issue_date] => 2023-07-20
[patent_title] => INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/688822
[patent_app_country] => US
[patent_app_date] => 2022-03-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 46440
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17688822
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/688822 | Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof | Mar 6, 2022 | Issued |
Array
(
[id] => 18511297
[patent_doc_number] => 20230227433
[patent_country] => US
[patent_kind] => A9
[patent_issue_date] => 2023-07-20
[patent_title] => INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/688822
[patent_app_country] => US
[patent_app_date] => 2022-03-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 46440
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17688822
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/688822 | Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof | Mar 6, 2022 | Issued |
Array
(
[id] => 19165798
[patent_doc_number] => 11981684
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-05-14
[patent_title] => Macrocyclic compounds and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/676942
[patent_app_country] => US
[patent_app_date] => 2022-02-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 20
[patent_figures_cnt] => 32
[patent_no_of_words] => 25677
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17676942
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/676942 | Macrocyclic compounds and uses thereof | Feb 21, 2022 | Issued |
Array
(
[id] => 18700051
[patent_doc_number] => 11786537
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-17
[patent_title] => Therapeutic inhibition affinity of copper (II) complex and their diazenyl pyridinone heterocyclic ligands against SARS-CoV2
[patent_app_type] => utility
[patent_app_number] => 17/670469
[patent_app_country] => US
[patent_app_date] => 2022-02-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 30
[patent_no_of_words] => 8471
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17670469
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/670469 | Therapeutic inhibition affinity of copper (II) complex and their diazenyl pyridinone heterocyclic ligands against SARS-CoV2 | Feb 12, 2022 | Issued |
Array
(
[id] => 17704498
[patent_doc_number] => 20220204504
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-30
[patent_title] => DEUTERATED COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/669950
[patent_app_country] => US
[patent_app_date] => 2022-02-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24571
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17669950
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/669950 | Deuterated colony stimulating factor-1 receptor (CSF-1R) inhibitors | Feb 10, 2022 | Issued |
Array
(
[id] => 19840119
[patent_doc_number] => 12252488
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-03-18
[patent_title] => HPK1 antagonists and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/650732
[patent_app_country] => US
[patent_app_date] => 2022-02-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 105131
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 651
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17650732
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/650732 | HPK1 antagonists and uses thereof | Feb 10, 2022 | Issued |
Array
(
[id] => 19233679
[patent_doc_number] => 20240190871
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-13
[patent_title] => KRASG12D INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/547515
[patent_app_country] => US
[patent_app_date] => 2022-02-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12411
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 1038
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18547515
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/547515 | KRASG12D INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Feb 8, 2022 | Pending |
Array
(
[id] => 17627209
[patent_doc_number] => 20220162224
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-26
[patent_title] => P38ALPHA MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/667898
[patent_app_country] => US
[patent_app_date] => 2022-02-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27601
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 79
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17667898
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/667898 | p38a mitogen-activated protein kinase inhibitors | Feb 8, 2022 | Issued |
Array
(
[id] => 17790341
[patent_doc_number] => 20220249432
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-11
[patent_title] => BAICALEIN ANALOGS FOR USE IN NEUROPROTECTION AND REGULATION OF IMMUNE REACTIVITY
[patent_app_type] => utility
[patent_app_number] => 17/650387
[patent_app_country] => US
[patent_app_date] => 2022-02-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7454
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 126
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17650387
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/650387 | Baicalein analogs for use in neuroprotection and regulation of immune reactivity | Feb 8, 2022 | Issued |
Array
(
[id] => 19396122
[patent_doc_number] => 12070451
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-08-27
[patent_title] => Sulfate salt of the free base of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide, pharmaceutical formulations, methods of manufacture and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/585145
[patent_app_country] => US
[patent_app_date] => 2022-01-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 47
[patent_figures_cnt] => 53
[patent_no_of_words] => 21788
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17585145
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/585145 | Sulfate salt of the free base of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide, pharmaceutical formulations, methods of manufacture and uses thereof | Jan 25, 2022 | Issued |
Array
(
[id] => 17533576
[patent_doc_number] => 20220112185
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-14
[patent_title] => NOVEL PHENYL PROPIONIC ACID DERIVATIVES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/559546
[patent_app_country] => US
[patent_app_date] => 2021-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11230
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 151
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17559546
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/559546 | NOVEL PHENYL PROPIONIC ACID DERIVATIVES AND USES THEREOF | Dec 21, 2021 | Abandoned |
Array
(
[id] => 19148725
[patent_doc_number] => 20240147846
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-02
[patent_title] => ORGANIC ELECTROLUMINESCENT ELEMENT AND ELECTRONIC DEVICE
[patent_app_type] => utility
[patent_app_number] => 18/256036
[patent_app_country] => US
[patent_app_date] => 2021-12-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35720
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18256036
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/256036 | ORGANIC ELECTROLUMINESCENT ELEMENT AND ELECTRONIC DEVICE | Dec 7, 2021 | Pending |
Array
(
[id] => 18877433
[patent_doc_number] => 20240000802
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-04
[patent_title] => DIFLUPREDNATE FOR REDUCING THE ADVERSE EFFECTS OF OCULAR INFLAMMATION
[patent_app_type] => utility
[patent_app_number] => 18/255207
[patent_app_country] => US
[patent_app_date] => 2021-12-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12518
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 68
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18255207
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/255207 | DIFLUPREDNATE FOR REDUCING THE ADVERSE EFFECTS OF OCULAR INFLAMMATION | Dec 2, 2021 | Pending |
Array
(
[id] => 18879009
[patent_doc_number] => 20240002378
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-04
[patent_title] => MERGED SCAFFOLD TAF1 INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/039386
[patent_app_country] => US
[patent_app_date] => 2021-11-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17176
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18039386
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/039386 | Merged scaffold TAF1 inhibitors | Nov 29, 2021 | Issued |
Array
(
[id] => 17982552
[patent_doc_number] => 20220348588
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-03
[patent_title] => 7-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME
[patent_app_type] => utility
[patent_app_number] => 17/532413
[patent_app_country] => US
[patent_app_date] => 2021-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27221
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17532413
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/532413 | 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | Nov 21, 2021 | Issued |
Array
(
[id] => 17959977
[patent_doc_number] => 20220340557
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-27
[patent_title] => ANTI-PARASITIC COMPOUNDS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/532036
[patent_app_country] => US
[patent_app_date] => 2021-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 65170
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17532036
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/532036 | Anti-parasitic compounds and uses thereof | Nov 21, 2021 | Issued |
Array
(
[id] => 17611444
[patent_doc_number] => 20220153723
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-19
[patent_title] => IRE1ALPHA INHIBITORS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/525778
[patent_app_country] => US
[patent_app_date] => 2021-11-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 62247
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 178
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17525778
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/525778 | IRE1a inhibitors and uses thereof | Nov 11, 2021 | Issued |